Developing scalable in-vivo genomic medicine for blood disorders
Location: Switzerland
Total raised: $3.15M
Investors 1
| Date | Name | Website |
| 08.11.2025 | Venture Ki... | venturekic... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 21.07.2026 | Pre-Seed | $2.96M | OCCIDENT |
| 15.06.2026 | - | $189.06K | Venture Ki... |
Mentions in press and media 13
| Date | Title | Description |
| 27.07.2026 | Biotech Disruptor Immitra Bio Secures CHF 2.4 Million for In-Vivo Gene Editing | Immitra Bio secured CHF 2.4 million pre-seed funding. The Geneva biotech develops a scalable in-vivo gene editing platform. Its lead candidate, IB-003, offers a potential one-time cure for inherited anemia. This mutation-agnostic technology... |
| 21.07.2026 | ImmitraBio secures CHF 2.4 million in pre-seed funding | Immitra Bio is developing a platform for scalable, one-time curative in-vivo gene editing therapies based on its novel mutation agnostic gene editing technology and digital target identification platform. The company’s approach is designed... |
| 21.07.2026 | Immitra Bio raises CHF 2.4 million to advance in-vivo gene editing platform | The biotech startup Immitra Bio, a Venture Kick and Venture Leaders alumnus, has secured CHF 2.4 million in pre-seed funding to advance its scalable in-vivo gene editing technology and lead candidate, IB-003. The round includes CHF 2.25 mil... |
| 19.06.2026 | Swiss biotechs display their innovations at BIO 2026 in San Diego | The BIO International Convention attracts over 1,600 exhibitors and 21,000 attendees who network intensively over 4 days, discover new opportunities and promising partnerships. The attendees benefit from a broad spectrum of life sciences a... |
| 16.06.2026 | Immitra Bio Secures Venture Kick Funding for Groundbreaking Stem Cell Therapy | Immitra Bio secured CHF 150,000 from Venture Kick. This funding propels a groundbreaking stem cell therapy. The Geneva biotech company develops an in-vivo approach. It works directly inside the body. This eliminates the need for chemotherap... |
| 15.06.2026 | Immitra Bio receives CHF 150,000 from Venture Kick | More than 7,000 rare genetic diseases affect an estimated 400 million people worldwide, yet 95% still lack an effective treatment. Current stem cell therapies for genetic disorders are often expensive, difficult to scale, and require inten... |
| 15.06.2026 | Immitra Bio receives CHF 150,000 from Venture Kick to reimagine stem cell therapy for rare diseases | More than 7,000 rare genetic diseases affect an estimated 400 million people worldwide, yet 95% still lack an effective treatment. Current stem cell therapies for genetic disorders are often expensive, difficult to scale, and require intens... |
| 04.05.2026 | InnoBooster supports three early-stage startups with CHF 450'000 | InnoBooster is an initiative of the Gebert Rüf Stiftung designed to support university students that have already entered the second stage of the Venture Kick program with up to CHF 150,000 for a maximum of 1.5 years. This funding allows s... |
| 08.12.2025 | Forbes 30Under30 spotlights Swiss innovators | Every year, Forbes’ 30under30 list identifies and honors individuals in the DACH region (Germany, Austria, Switzerland) whose initiatives, innovation, and entrepreneurial mindset help solve society and business challenges. The newly publis... |
| 27.02.2025 | Three Geneva startups including a sustainable mobility project granted FIF Funding | Sustainable mobility company Miloo (pictured), as part of DNA Mobile SA, was granted a Growth Loan for their state-of-the-art electric bicycles. Independent of the FONGIT-Modus partnership, the FIF committee awarded life sciences startup I... |
Show more